A Randomized, Two-arm, Open Label Study to evalUate the Effect of a Smart Phone-based Patient Support Tool On Patient AdheRence of Treatment in Stable Angina Patients Prescribed Beta-blockers in China (SUPPORT)
A Randomized, Two-arm, Open Label Study to evalUate the Effect of a Smart Phone-based Patient Support Tool On Patient AdheRence of Treatment in Stable Angina Patients Prescribed Beta-blockers in China (SUPPORT)
The present study aims to enhance the adherence of beta-blockers by Patient Support Tool
 through a smart phone application and a wristband, subsequently reduce the risk of angina
 attacks in patients with stable angina pectoris.
To control heart rate in terms of guidelines in patients with stable angina pectoris reduces
 risk of cardiovascular events, rehospitalization, and death effectively. Using beta blockers
 is an efficient therapy to management the HR in SAP patients. However, the recent
 epidemiological studies have provided evidences that the rate of beta blocker prescribed and
 used was inadequate, as the first-line therapy to CAD patients with the usage rate less than
 30%. Several studies showed that with a reminder supported by smart phones and wearable
 devices, the adherence of management of patients with chronic disease could be improved
 significantly.Thus,the present study aims to enhance the adherence of beta-blockers by
 Patient Support Tool through a smart phone application and a wristband, subsequently reduce
 the risk of angina attacks.
Inclusion Criteria:

 1. Aged 18-70 years;

 2. Stable angina pectoris;

 3. Indicated for beta blockers;

 4. HR ≥ 60bpm;

 5. Patient must have a smart phone that is compatible with the Patient support tool at
 their disposal and are comfortable with using of interactive smart phone applications.
 The required specification for the phone will be determined after completed testing;

 6. Ability to read, understand and write Chinese;

 7. Beta-blockers naïve or with no Beta-blocker use during the last 1 month.

 Exclusion Criteria:

 1. Previous myocardial infarction during the recent 1 year;

 2. Cardiac shock or unstable heart failure (NYHA III);

 3. SBP<100 mmHg;

 4. Sick sinus syndrome;

 5. II-III degree atrioventricular block;

 6. Existing contraindication for Beta-blockers or allergic to beta-blockers;

 7. Participation in another clinical study with a beta blocker during the last 3 months;

 8. Inability to sign the informed consent form;

 9. Females during pregnancy and lactation and women of child bearing potential planning
 to be pregnant within 24 weeks.;

 10. Patients who withdraw from this study for any reason cannot re-enter the study;

 11. Life expectancy < 1 year;

 12. Severe asthma or COPD;

 13. Severe peripheral vascular disease;